🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology · Phase II

Oncology programs at Phase II — ClinicalTrials.gov pipeline intelligence.

Programs
2,640

Quick answer

Oncology Phase II programs: NovaPharmaNews indexes 2,640 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Page 8 of 55

  1. B013

    BRIGHT MINDS BIOSCIENCES INC.

    Platinum-resistant Recurrent Ovarian Cancer

    phase 2 small molecule active

    1 trial

  2. B10 L-BPA Injection

    Heron Therapeutics

    Malignant Brain Tumors

    phase 2 small molecule active

    1 trial

  3. BAX69 + infusional 5-FU/LV

    Takeda

    Metastatic Colorectal Cancer

    phase 2 mab terminated

    1 trial

  4. BAX69 Single-Route Arm

    Takeda

    Refractory Ovarian Cancer With Recurrent Symptomatic Malignant Ascites

    phase 2 mab terminated

    1 trial

  5. BAY 1841788, DEGARELIX , LEUPRORELIN , TRIPTORELIN , GOSERELIN , TRIPTORELIN PAMOATE

    Ningbo Cancer Hospital

    Hormone Naive Prostate Cancer

    phase 2 small molecule active

    1 trial

  6. BAY 2927088 Bayer (CM), BAY 2927088 Bayer (CM), BAY 2927088, BAY 2927088 Bayer

    Bayer AG

    HER2 mutation, Advanced solid tumors

    phase 2 small molecule active

    1 trial

  7. BAY 3713372 Bayer, BAY 3713372 Bayer, -, -, -, -

    Bayer AG

    MTAP-deleted Solid Tumors

    phase 2 small molecule active

    1 trial

  8. BAY 73-4506, AVELUMAB

    The George Institute

    Adult patients with advanced or metastatic solid tumors

    phase 2 small molecule active

    1 trial

  9. BAY 73-4506, BAY 734506

    Bayer AG

    Solid malignant tumors

    phase 2 small molecule active

    1 trial

  10. BAY2757556 (Larotrectinib, Vitrakvi)

    Bayer HealthCare AG

    Solid Tumors Harboring NTRK Fusion

    phase 2 small molecule completed

    1 trial

  11. BB-401

    Benitec Biopharma

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule completed

    1 trial

  12. BBP-398, CETUXIMAB, ADAGRASIB

    Bristol-Myers Squibb Australia Pty Ltd

    Oncology, NSCLC and CRC

    phase 2 small molecule active

    1 trial

  13. BC1 cell line

    BriaCell Therapeutics

    Breast Cancer

    phase 2 mab active

    1 trial

  14. BCG (50mg/instillation) + N-803 (400 μg/instillation)

    Immunitybio Ireland Limited

    Non-muscle Invasive Bladder Cancer

    phase 2 mab active

    1 trial

  15. BCG-MEDAC, poudre et solvant pour suspension intravésicale, PD1IL2v iMAb

    Hoffmann-La Roche

    BCG-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC)

    phase 2 small molecule active

    1 trial

  16. BCMA CAR-T

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Multiple Myeloma, Plasma Cell Leukemia

    phase 2 mab active

    1 trial

  17. BCX-1777

    Biocryst

    Leukemia, Lymphocytic

    phase 2 small molecule completed

    1 trial

  18. BDB001

    Eikon Therapeutics

    Tumor, Solid

    phase 2 small molecule completed

    1 trial

  19. BDC-1001

    Bolt Biotherapeutics

    Metastatic Breast Cancer

    phase 2 small molecule terminated

    1 trial

  20. BDC-1001

    Bolt Biotherapeutics

    HER2-positive Solid Tumors

    phase 2 small molecule terminated

    1 trial

  21. BDC-1001, PERTUZUMAB

    Bolt Biotherapeutics

    HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2–POSITIVE METASTATIC BREAST CANCER

    phase 2 small molecule active

    1 trial

  22. BDC-4182

    Bolt Biotherapeutics

    Gastric Cancer Adenocarcinoma Metastatic

    phase 2 small molecule active

    1 trial

  23. BEAM-201

    Beam Therapeutics

    Lymphoblastic Lymphoma

    phase 2 mab active

    1 trial

  24. BENDAFOLIN 10 mg/ml Injektionslösung, Gemcitabin HEXAL® 40 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Benda-5 FU 50 mg/ml Injektionslösung, Onivyde pegylated liposomal 4.3 mg/ml concentrate for dispersion for infusion, Irinotecan Bendalis 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, AZD0901

    AstraZeneca AB

    Gastric Cancer, Gastroesophageal Junction Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer

    phase 2 small molecule active

    1 trial

  25. BENDAMUSTINE , CYTARABINE , VENETOCLAX , RITUXIMAB

    Fondazione Telethon ETS

    Mantle Cell Lymphoma

    phase 2 small molecule active

    1 trial

  26. BEVACIZUMAB, ATEZOLIZUMAB

    Pari Pharma GmbH

    liver transplanted patients with advanced hepatocellular carcinoma

    phase 2 small molecule active

    1 trial

  27. BEVACIZUMAB, DC-VACCINE_IRSTIRCCS, Lonsurf 20 mg/8.19 mg film-coated tablets, VEGZELMA 25 mg/mL concentrate for solution for infusion, VEGZELMA 25 mg/mL concentrate for solution for infusion, Lonsurf 15 mg/6.14 mg film-coated tablets, KEYTRUDA 25 mg/mL concentrate for solution for infusion, BEVACIZUMAB

    Istituto Gentili S.r.l.

    Metastatic colorectal cancer

    phase 2 small molecule active

    1 trial

  28. BEVACIZUMAB, IRINOTECAN, FOLINIC ACID, Telisotuzumab adizutecan, FLUOROURACIL

    AbbVie Deutschland GmbH & Co. KG

    Colorectal Cancer

    phase 2 small molecule active

    1 trial

  29. BEVACIZUMAB, PEMBROLIZUMAB, VINORELBINE, GEMCITABINE, NIVOLUMAB, PEMETREXED, PACLITAXEL, CARBOPLATIN

    CERO THERAPEUTICS HOLDINGS, INC.

    Non Small Cell Lung Cancer, Interstitial Lung Disease

    phase 2 small molecule active

    1 trial

  30. BGB-10188

    BEONE MEDICINES AUS PTY LTD

    Chronic Lymphocytic Leukemia

    phase 2 small molecule completed

    1 trial

  31. BGB-11417

    BEONE MEDICINES AUS PTY LTD

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  32. BGB-11417

    BEONE MEDICINES AUS PTY LTD

    Leukemia

    phase 2 small molecule active

    1 trial

  33. BGB-11417, POSACONAZOLE, Azacitidine betapharm 25 mg/mL powder for suspension for injection, BGB-11417, BGB-11417, AZACITIDINE

    BEONE MEDICINES AUS PTY LTD

    Myeloid malignancies (acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and myelodysplastic syndrome/myeloproliferative neoplasms (MDS/MPN.

    phase 2 small molecule active

    1 trial

  34. BGB-11417, Zanubrutinib, BGB-11417, BGB-11417, BGB-11417

    BEONE MEDICINES AUS PTY LTD

    Previously Untreated Chronic Lymphocytic Leukemia

    phase 2 small molecule active

    1 trial

  35. BGB-11417, Zanubrutinib, BGB-11417, BGB-11417, BGB-11417

    BEONE MEDICINES AUS PTY LTD

    previously untreated chronic lymphocytic leukemia (CLL)

    phase 2 small molecule active

    1 trial

  36. BGB-A317

    The First People's Hospital of Lianyungang

    Gastric Cancer

    phase 2 small molecule completed

    1 trial

  37. BGB-A445

    BEONE MEDICINES AUS PTY LTD

    Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  38. BGJ398 (infigratinib)

    BridgeBio Oncology Therapeutics

    Advanced Cholangiocarcinoma

    phase 2 small molecule terminated

    1 trial

  39. BI 907828, Ezabenlimab, BI 907828, BI 907828

    The George Institute

    Adult patients with locally advanced/metastatic solid tumors

    phase 2 small molecule active

    1 trial

  40. BI-754091 plus afatinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Esophageal Squamous Cell Carcinoma (ESCC)

    phase 2 small molecule completed

    1 trial

  41. BINIMETINIB, IPILIMUMAB, NIVOLUMAB, PEMBROLIZUMAB, IPILIMUMAB, ENCORAFENIB

    Pfizer Australia Pty Ltd

    Metastatic or unresectable locally advanced BRAF V600E/K mutation positive melanoma

    phase 2 small molecule active

    1 trial

  42. BL-B01D1

    Sichuan Baili Pharmaceutical Co.,

    Cervical Cancer

    phase 2 small molecule active

    1 trial

  43. BL-B01D1

    Sichuan Baili Pharmaceutical Co.,

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  44. BL0020

    Shanghai Best-Link Bioscience

    Small Cell Carcinoma of Lung

    phase 2 small molecule active

    1 trial

  45. BLEOMYCIN

    Fondazione Telethon ETS

    colorectal cancer

    phase 2 small molecule active

    1 trial

  46. BLEOMYCIN , KEYTRUDA 25 mg/mL concentrate for solution for infusion, VINBLASTINE , CYCLOPHOSPHAMIDE , ETOPOSIDE , DACARBAZINE , PREDNISOLONE, VINCRISTINE , PREDNISONE, DOXORUBICIN

    Merck Sharp and Dohme

    Classical Hodgkin lymphoma in children and young adults

    phase 2 small molecule active

    1 trial

  47. BLEOMYCIN, CISPLATIN

    Fondazione Telethon ETS

    patients with newly diagnosed or recurrent high-grade or initially invasive precancerous squamous lesions of the vulva and non-invasive vulvar Paget's disease

    phase 2 small molecule active

    1 trial

  48. BLEOPRIM 15 mg polvere per soluzione iniettabile, Carboplatino AHCL 10 mg/ml Concentrato per soluzione per infusione

    Istituto Gentili S.r.l.

    relapsing vulvar carcinoma already subjected to multiple treatments

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many oncology Phase II programs exist?

2,640 programs match both the therapeutic area and stage filters in our published index.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.